At an old Amgen facility tucked just beyond the Rockies. In a warehouse behind a Walmart supercenter in Durham, North Carolina. On a long-time Bristol Myers Squibb site outside Princeton. The tech has emerged, and now the arms race to physically build a generation of gene therapies has begun.

Novartis will spend $500 million scaling its gene therapy manufacturing efforts, Reuters reported today. Thatll put it nearly on par with Pfizer, who committed $600 million for its facilities even before any of its gene therapies have been approved. Together, 11 companies Reuters surveyed will spend $2 billion on gene therapy production.

Additionally, the Boston Globereported today that Vertex had completed its search for a gene therapy research and manufacturing campus in Boston, settling on a 256,000 square-foot center at the Raymond Flynn Marine Industrial Park.

Unlock this story instantly and join 66,400+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

More:
Make that 2 new sickle cell disease blockbuster hopefuls OK'd by the FDA in just a few days - Endpoints News

Comments are closed.